Alnylam Pharmaceuticals, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO to be $1,400 million to $1,500 million and net revenues from collaborations and royalties to be $325 million to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
148.4 USD | -1.06% | +0.45% | -22.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.45% | 18.78B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B | |
-3.38% | 9.6B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024